2016-06-01 19:21:38 UTC

Sofosbuvir Plus Ribavirin Shows Promise in Complicated HCV Genotype 2 Patients

June 1, 2016

Phase 4 study results published in CGH find that this treatment combo is effective in almost 80 percent of HCV genotype 2 patients with cirrhosis.

A new Clinical Gastroenterology and Hepatology (CGH) article in press highlights the results of a Phase 4, open-label study to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus (HCV) genotype 2 infection and compensated cirrhosis.

The research team, led by Samuel B. Ho, MD, conclude that 12-weeks treatment with sofosbuvir and ribavirin led to a sustained virologic response (SVR) in almost 80 percent of veterans with HCV genotype 2 infection, compensated cirrhosis and multiple comorbidities, regardless of their treatment history.

The presence of depression, post-traumatic stress disorder or substance use did not impact the treatment outcome in this study, indicating that patients with these coexisting conditions can expect to achieve SVR rates similar to those without them.

This study represents the largest group of HCV genotype 2 patients with cirrhosis studied in a prospective trial of sofosbuvir and ribavirin to date. Review the full study on the CGH website (login required).

More on Cirrhosis

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

Final days to save on AGA Postgraduate Course

April 10, 2018

Early bird deadline is April 18 – last chance to save $75.